Biogen Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Biogen Inc. (BIIB) holds an ST Score of 57.5 out of 100 (B-), with its strongest factor being Sentiment (A+) and its weakest Growth (D+). Analysts rate BIIB Buy across 49 ratings with a $245.88 average price target (+0.1% vs the current $219.07).
- Strongest
- SentimentA+
- Weakest
- GrowthD+
All factor grades
- SentimentA+
- MomentumA
- Financial StrengthB
- ForecastB
- ValuationB-
- ProfitabilityC-
- GrowthD+
- Piotroski4/9
Contact
BIIB stock: frequently asked questions
What is BIIB's ST Score?
Biogen Inc. (BIIB) has an ST Score of 57.5 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BIIB a buy, sell, or hold?
Wall Street's consensus rating on BIIB is Buy based on 49 analyst ratings. Our own ST Score grades it B- (57.5/100). This is data, not investment advice — always do your own research.
What is BIIB's valuation grade?
Biogen Inc. (BIIB) earns a valuation grade of B-, measured against Drug Manufacturers - General peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BIIB's growth grade?
Biogen Inc. (BIIB) earns a growth grade of D+, measured against Drug Manufacturers - General peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BIIB's profitability grade?
Biogen Inc. (BIIB) earns a profitability grade of C-, measured against Drug Manufacturers - General peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BIIB's financial strength grade?
Biogen Inc. (BIIB) earns a financial strength grade of B, measured against Drug Manufacturers - General peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BIIB?
The average analyst price target for Biogen Inc. (BIIB) is $245.88 from 49 analysts, which is +0.1% versus the recent price of $219.07.
What is BIIB's Piotroski score?
Biogen Inc. (BIIB) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.